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PET-CT-guided interventions
in the management of FDG-positive lesions
in patients suffering from solid malignancies:
initial experiences
Abstract Positron emission tomo-
graphy–computed tomography
(PET-CT) has gained widespread ac-
ceptance as a staging investigation in
the diagnostic workup of malignant
tumours and may be used to visualize
metabolic changes before the evolu-
tion of morphological changes. To
make histology of PET findings
without distinctive structural changes
available for treatment decisions, we
developed a protocol for multimodal
image-guided interventions using an
integrated PET-CT machine. We re-
port our first experience in 12 patients
admitted for staging and restaging of
breast cancer, non-small cell lung
cancer, cervical cancer, soft tissue
sarcoma, and osteosarcoma. Patients
were repositioned according to the
findings in PET-CT and intervention
was planned based on a subsequent
single-bed PET-CT acquisition of the
region concerned. The needle was
introduced under CT guidance in a
step-by-step technique and correct
needle position in the centre of the
FDG avid lesion was assured by
repetition of a single-bed PET-CT
acquisition before sampling. The
metabolically active part of lesions
was accurately targeted in all patients
and representative samples were ob-
tained in 92%. No major adverse
effects occurred. We conclude that
PET-CT guidance for interventions is
feasible and may be promising to
optimize the diagnostic yield of CT-
guided interventions and to make
metabolically active lesions without
morphological correlate accessible to
percutaneous interventions.
Keywords Image-guided
intervention . Percutaneous biopsy .
Positron emission tomography .
PET-CT . FDG
Introduction
Accurate staging is a prerequisite for an individualised,
risk-adapted therapy of cancer patients. In this context,
positron emission tomography–computed tomography
(PET-CT) has become an inherent part of diagnostic
workup, e.g. in staging lung cancer [1], in restaging and
patient selection for metastasectomy in colorectal cancer
[2] and in staging and restaging of breast cancer [3, 4]. As
PET—for example using the glucose analogue [18F]
fluorodeoxyglucose (FDG)—visualizes metabolic changes
in tumour tissues, even lesions without morphological
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correlates can be depicted. In a clinical context, early and
reliable detection of distant metastases is crucial, as these
change stage grouping and thus the therapeutic approach
from a curative to a palliative intention. As patients with
distant metastatic disease usually have incurable disease, the
local and systemic therapies tend to be less aggressive and
associated with fewer side effects than those used for curative
purposes. Therefore, optimal staging with PET-CT may
prevent patients in a palliative situation from receiving futile
but burdensome therapies at the expense of quality of life.
However, despite the overall good sensitivity and
specificity of PET-CT, e.g. 83% and 91% for lung cancer
staging [5], a number of benign conditions mimicking
metastatic FDG uptake have been described, eventually
leading to an overstaging and undertreatment of patients
[6]. Lardinois et al. found that up to half of solitary
extrapulmonary FDG accumulations found during PET-CT
staging of lung cancer may represent unrelated malig-
nancies or benign disease, e.g. benign tumours or inflam-
matory changes [7]. The histological assessment of
singular hypermetabolic lesions thus appears to be
imperative, especially in the absence of confirmative
structural changes. Percutaneous image-guided biopsies
are widely used as a minimally invasive alternative to open
surgical biopsy. However, lesions which are only visible on
PET images may not be accessible to CT-guided biopsy.
We therefore developed a combined approach using the
metabolic and topographic information of PET together
with CT navigation. We report our first experience in
performing multimodal image-guided interventions using a
protocol with an integrated PET-CT device.
Materials and methods
Patients
Interventions under PET-CT guidance in 12 patients
(7 female, 5 male) were retrospectively reviewed in
accordance with the regulations of the local ethics
committee. All patients were referred to the Department of
Nuclear Medicine for PET-CT staging or restaging of
malignancies. Median age of patients was 59 years (mean
57 years, range 18–84 years). Patients suffered from or had a
history of breast cancer (n=5), non-small cell lung cancer
(NSCLC, n=4), cervical cancer (n=1), pelvic soft tissue
sarcoma (n=1) and osteosarcoma of the femur (n=1).
FDG PET-CT
Positron emission tomography was performed using an
integrated PET-CT system which combines a 16-slice
helical CT machine with high-resolution PET (Biograph 16
Hi-Rez, Siemens Medical Solutions). All patients fasted for
at least 6 h before examination. Image acquisition for a
PET-CT from neck to pelvis was done 90 min after
intravenous injection of 5–7 MBq FDG/kg body weight
with a low-dose unenhanced computed tomography
(reconstructed slice thickness 2 mm) and emission images
were obtained 3 min per bed position (length of body
examined 16.2 cm) from the neck to the pelvis (5–7 bed
positions). When interventions were performed on the day
of PET-CT, no additional FDG was injected, but the
acquisition time for emission images 120–180 min after
injection was prolonged to 5 min per bed position to assure
adequate image quality. For interventions on a separate day
3–5 MBq FDG/kg body weight was injected and the
acquisition time was 5 min per bed position 60–90 min
after injection. Blood glucose level was below 10 mmol/l in
all patients. Images were evaluated qualitatively and
maximum standardized uptake values were measured. No
SUV cutoff values for the distinction of benign from
malign lesions were applied.
Intervention
The indication for biopsy was based on findings in FDG
PET-CT and the consultation with the treating physician.
Only lesions of potential impact on the further therapeutic
concept were biopsied. Punctures were performed under
supervision of or by an experienced interventional radiol-
ogist. All patients gave written consent before the
intervention. Patients underwent biopsy either on the
same day as whole body PET-CT or were scheduled on a
separate day. All patients were repositioned depending on
the localization of the lesion concerned and a PET-CT
acquisition of a single bed position of the region of interest
was obtained in prone or supine position. Based on this
PET-CT dataset (length of body examined 16.2 cm), the
access path was defined based according to the presenta-
tion of the metabolically active lesion of interest.
Interventions were performed under aseptic conditions,
local anaesthesia and additional sedation with midazolam,
if necessary. The needle was introduced under CT guidance
in a step-by-step technique with respect to individual
anatomical landmarks visible in CT, as defined according
to the PET-CT dataset acquired in biopsy position. The
correct needle position in the centre of the FDG avid lesion
was assured by repetition of a single-bed PET-CT acqui-
sition before sampling. If necessary, the biopsy needle was
repositioned depending on the result of the control images.
Bone and soft tissue biopsy systems were chosen
depending on localization and depth of the lesion. One or
more samples were obtained. In one patient a soft tissue
mass was marked with a localization coil and a localization
wire before resection. Single-bed PET-CT acquisition was
repeated in small lesions after sampling to evaluate the
sampling of the active tissue. Total time for single bed PET-
CTwas 12 min in nine patients and 18 min in three patients
for two and three repetitive acquisitions, respectively.
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Results
A total of 14 sites were punctured in 12 patients. PET-CT-
guided intervention was technically successful, i.e. the
metabolically active part of lesions was successfully
targeted in all patients and in 12 of 13 metabolically active
sites representative tissue samples could be obtained
(92%). In 10 of 12 patients a definite diagnosis was
possible based on the obtained samples. According to CT,
the median diameter of all lesions punctured was 9 mm
(mean 16 mm, range 7–40 mm). The median diameter of
bone lesions was 8 mm (mean 9 mm, range 8–10 mm),
while soft tissue lesions had a median diameter of 15 mm
(mean 19 mm, range 7–40 mm). Two lesions were not
delineable in CT; seven lesions did not present a
pathological appearance in CT and could be delineated
retrospectively in CT together with the PET information.
Two lesions were centrally necrotic. The mean depth of
lesions was 74 mm (median 70 mm) without major
differences between bone and soft tissue lesions (Table 1).
Bone biopsies
Bone biopsies were performed in four patients with breast
cancer (two primary staging, two restaging) and in one patient
with NSCLC (primary staging) and osteosarcoma (staging),
respectively. All patients with breast cancer presented with
solitary bone lesions. In two patients lesions had no charac-
teristic morphological appearance for metastatic disease, one
had increased FDG uptake in the posterior part of the left
acetabulum without any morphological correlate (Fig. 1) and
one had minor changes in a vertebral body incongruent with
the activity distribution. In patients 2, 4 and 5 diagnosis of
bone metastases was confirmed histologically. Patient 5 had
only a subtle bone marrow infiltration by cells originating
from breast cancer. Patient 6 with osteosarcoma of the right
femur and a suspicious rib lesion in an initial skeletal
scintigram was biopsied after one cycle of chemotherapy
according to a tumour board decision despite absence of high
FDG uptake in PET-CT. In this case, according to the
morphological and metabolic appearance only sclerosis was
detected, but no sign of malignancy. However, the result
remained inconclusive and taking into account a potentially
false-negative biopsy a rib resection was performed 4 months
later, showing scattered tumour cells in the specimen. In
patient 8 with newly diagnosed NSCLC bilateral symmetric
pulmonary, hilar and mediastinal uptake suggested sarcoido-
sis. PET-CT-guided biopsy revealed a bone metastasis in a
morphologically indeterminate lesion scaled 10 mm in a
thoracic vertebral body. In patient 10, who had concomitant
uptake in the right lung and in hilar lymph nodes (differential
Table 1 Patient characteristics
Diagnosis Localization of biopsy Lesion Histology Success
Diameter Depth (cm) Metabolism Technical Clinical
1 Cervical cancer Mediastinum 2 cm 9 + Cervical cancer Yes Yes
2 Breast cancer Lumbar spine 8 mm*** 11 + Breast cancer Yes Yes
3 Soft tissue sarcoma Lung 11 cm* 7 + Soft tissue sarcoma Yes Yes
4 Breast cancer Scapula 8 mm*** 3 + Breast cancer Yes Yes
5 Breast cancer Acetabulum ** 10 + Breast cancer Yes Yes
6 Osteosarcoma Rib 8 mm 6 − Sclerosis Yes No
7 Breast cancer Parasternal, clavicular and
paravertebral LN
7 mm*** 7 + Breast cancer Yes Yes
7 mm*** 4
9 mm*** 6
8 NSCLC Thoracal spine 10 mm*** 7 + NSCLC Yes Yes
9 NSCLC Thorax 5×3 cm 3 + NSCLC Yes Yes
10 Breast cancer Thoracal spine ** 8 + Breast cancer Yes No
11 NSCLC Supraclavicular LN 7 mm*** 5 + Sinus histiocytosis Yes Yes
12 NSCLC Pelvic LN 4 cm 13 + Prostate Cancer Yes Yes
*Subtotal necrosis, diameter of the metabolically active region approx. 2×3 cm
**Not delineable in CT
***No distinctive morphological alterations in CT
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diagnosis lung cancer), atypical cells were found, but a
definite diagnosis was not possible due to absence of any
marker expression in immunohistochemical staining after
decalcification of the specimen. Subsequent lung resection
showed the same cell type again, but diagnosis of breast
cancer recurrence was finally possible.
Soft tissue biopsies
Soft tissue interventions included three patientswith suspected
or proven NSCLC (primary staging) and one patient with
cervical cancer (restaging), breast cancer (restaging) and a
pararectal soft tissue sarcoma (restaging), respectively. In
patient 1 with a history of cervical cancer and in patient 7 with
breast cancer second malignancies were taken into account
based on the distribution and pattern of FDG uptake in PET-
CT. However, recurrences of the known primary tumours
were confirmed in both patients. Patient 3 with a history of a
pararectal soft tissue sarcoma presented with a total atelectasis
of his left lung and pleural effusion. A preceding CT was
equivocal and an infectious cause of the basal tumour mass
had been suggested. PET-CT clearly detected areas with
increased FDG uptake, i.e. vital tissue in the collapsed lung,
which were biopsied and showed poorly differentiated
sarcomatous tissue (Fig. 2). In three further patients with
NSCLC indications were verification of a chest wall infiltra-
tion (patient 9), clarification of FDG uptake in a solitary
supraclavicular lymph node (patient 11, sinus histiocytosis)
and in a singular pelvic lymph node (patient 12, prostate
cancer).
Side effects and complications
Seven of 12 patients were treated on an outpatient basis and
were released after 2–4 h of supervision; five patients were
hospitalized overnight for logistic reasons. All patients
were released in good physical status. No serious adverse
effects (e.g. major bleeding, pneumothorax, infection)
occurred. In two patients venous bleeding developed which
stopped spontaneously in one and was successfully treated
in another patient on acetylsalicylic acid at the time of
biopsy by injecting a blood clot through the puncture
cannula. An unenhanced CT image revealed a small c-
shaped hematoma around the lymph node which had been
punctured. Among four patients with chest interventions no
pneumothorax occurred. Interventions were well tolerated
under local anaesthesia. Four patients had midazolam 2–
5 mg for short-term sedation.
Discussion
Positron emission tomography has gained widespread
acceptance as a staging investigation in the diagnostic
workup of many tumours and was shown to have the
potential to clarify true stage grouping in up to one third of
patients after conventional staging [1–4, 8–10]. However,
false-positive results may occur in about 10% of all patients
[11–13]. Therefore, having the therapeutic impact of
distant metastases in mind, suspicious PET-CT findings
have to be evaluated prudently. Assumed metastases may
only be regarded as relevant for therapeutic decisions if
they can be verified histologically. This is especially true in
cases of singular and morphologically indeterminate
findings exclusively visualized by PET.
Image-guided punctures are well established in the
radiological community. Even though success rates for CT-
guided biopsies of morphologically clearly circumscribed
lesions are reported to range between 70 and 90% [14, 15],
the false-negative rate of only PET positive lesions may be
substantially higher. As a result of the lack of functional
information CT puncture can be negative even though a
Fig. 1 PET-CT-guided biopsy of a bone lesion not visible in CT.
The semiquantitatively measured activity (SUV) in the region
concerned is reduced after biopsy. Histology revealed a breast
cancer metastasis. a CT, b PET-CT, c PET-CT with decreased
activity of the lesion after biopsy
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malignant disease is present, e.g. when puncturing the
wrong nodule or when taking a biopsy from a part of a
lesion which is not representative. Problems may occur
when PET imaging and interventions are performed by
different persons, at different time points, using different
devices and having the patient positioned differently. In
order to increase the success rate of image-guided biopsies
and to decrease the number of second or even third image-
guided biopsies, it would be helpful to puncture the part of
the lesion presenting the strongest metabolism.
We describe our first experience with a protocol for PET-
CT-guided interventions. We used an integrated PET-CT
system and combined two well-established methods—PET
imaging and CT-guided navigation—in close collaboration
with an interdisciplinary team of specialists in nuclear
medicine and interventional radiology to make lesions,
which are characterized by metabolic properties more than
by morphological abnormalities, accessible for histological
verification.
To the best of our knowledge this is the first report
describing PET-CT-guided interventions employing inte-
grated PET-CT in patients suffering from solid tumours. In
our series of 12 consecutive patients PET-CT-guided
intervention was technically successful in all patients.
Needle positioning guided by PET-CT, similar to what has
been described by Veit et al. in an ex vivo liver model [16],
proved to be feasible and no relevant complication
occurred in a clinical routine setting. PET-CT-guided
interventions had an additional clinical impact in 50% of
the patients.
The advantages of this new approach are obvious. PET-
CT-guided biopsies offer the possibility to directly punc-
ture the metabolically active tissue of relevance—even if
structural landmarks are missing. Beside this, the metabo-
lically active, i.e. vital, part of a lesion can be targeted to
make sure that representative samples are obtained and
futile biopsy attempts, and the inherent strain for the
patient, may be avoided. According to our experience, even
small lesions without any morphologically distinctive
feature can be punctured reliably and the correct needle
positioning can be ascertained by a repeated PET-CT
acquisition of the region concerned before tissue sampling.
A certain drawback of PET-CT-guided biopsy in a step-
by-step technique is the fact that interventions are rather
time consuming and, given the occupancy of the PET-CT
system, cost-intensive. Although we achieved a high
diagnostic accuracy in our initial 12 patients without any
major side effects, we are aware that our retrospective
evaluation bears several limitations. First of all, the sample
size is relatively small. In a larger series, the rate of
complications may be expected in the range of CT-guided
punctures, as methodology of PET-CT-guided interven-
tions is similar to the established CT-guided punctures.
Potentially, the prolonged time needed and inconvenience
for the patient might even lead to an increased number of
side effects, although this was not observed in our small
series.
Conclusion
PET-CT guidance is feasible and may be a promising new
technique in patients with otherwise not or at least not
reliably accessible metabolically active lesions. PET-CT-
guided interventions may help to reduce the risk of possible
under- or overtreatment resulting from false stage grouping
even in borderline cases of metabolically active lesions
without morphological correlate. Further evaluation of
clinical impact and cost-efficiency in larger trials is
necessary.
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Fig. 2 Determination of opti-
mal location for sampling, i.e.
vital tumour tissue, in a subtotal
necrotic pulmonary mass ac-
cording to metabolic activity.
Histology revealed a metastasis
of a soft tissue sarcoma. a CT, b
PET-CT-guided biopsy of the
focus with highest FDG uptake
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